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The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic
retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world,
with clusters of high endemicity located often nearby areas where the virus is nearly
absent. The main HTLV-1 highly endemic regions are the Southwestern part of Japan,
sub-Saharan Africa and South America, the Caribbean area, and foci in Middle East and
Australo-Melanesia. The origin of this puzzling geographical or rather ethnic repartition is
probably linked to a founder effect in some groups with the persistence of a high viral
transmission rate. Despite different socio-economic and cultural environments, the HTLV-1
prevalence increases gradually with age, especially among women in all highly endemic
areas. The three modes of HTLV-1 transmission are mother to child, sexual transmission,
and transmission with contaminated blood products. Twenty years ago, de Thé and Bom-
ford estimated the total number of HTLV-1 carriers to be 10–20 millions people. At that time,
large regions had not been investigated, few population-based studies were available and
the assays used for HTLV-1 serology were not enough specific. Despite the fact that there
is still a lot of data lacking in large areas of the world and that most of the HTLV-1 studies
concern only blood donors, pregnant women, or different selected patients or high-risk
groups, we shall try based on the most recent data, to revisit the world distribution and the
estimates of the number of HTLV-1 infected persons. Our best estimates range from 5–10
millions HTLV-1 infected individuals. However, these results were based on only approxi-
mately 1.5 billion of individuals originating from known HTLV-1 endemic areas with reliable
available epidemiological data. Correct estimates in other highly populated regions, such
as China, India, the Maghreb, and East Africa, is currently not possible, thus, the current
number of HTLV-1 carriers is very probably much higher.
Keywords: HTLV-1, HTLV-1 epidemiology, HTLV-1 world distribution, HTLV-1 in Europe, HTLV-1 in Africa, HTLV-1 in
the Americas, HTLV-1 in Asia, HTLV-1 in Oceania
INTRODUCTION
Very rapidly after HTLV-1 discovery and its association with adult
T-cell leukemia (ATL), several studies were initiated both by Amer-
ican and Japanese researchers, to get insights into the distribution,
the transmission modes, as well as the origin of HTLV-1.
Thus, as soon as 1982–1984, important works demonstrated
clearly that Japan was a high endemic area for HTLV-1. Interest-
ingly, since the first studies, the geographic distribution of HTLV-1
carriers is quite uneven in Japan and the greatest prevalence is
observed in Southwestern Japan (Kyushu island and the Okinawa
archipelago). The origin of such a peculiar distribution is still the
matter of several hypotheses (Ishida and Hinuma, 1986; Miura
et al., 1994; Eguchi et al., 2009; Watanabe, 2011).
Nearly concomitantly to the initial papers by the Japanese
groups, the US teams demonstrated that the Caribbean area
was also endemic for HTLV-1. Soon after, ATL patients were
reported in the Caribbean community living in the United King-
dom (Catovsky et al., 1982). Such data, together with some early
epidemiological studies showing an HTLV-1 seroprevalence in
serum samples from inhabitants originating from different African
countries, indicated then that such a retrovirus was also endemic
in some areas of the African continent (Biggar et al., 1984; Hun-
smann et al., 1984; Saxinger et al., 1984; de-The et al., 1985; de The
and Gessain, 1986; Delaporte et al., 1989a,b, 1991; Ouattara et al.,
1989; Verdier et al., 1989, 1994; Goubau et al., 1990; Dumas et al.,
1991; Schrijvers et al., 1991).
The simian counterpart of HTLV-1 was also rapidly discovered,
based on the findings of STLV-1 in several monkey species from
Asia and Africa (Hunsmann et al., 1983; Guo et al., 1984; Hayami
et al., 1984; Homma et al., 1984; Becker et al., 1985; Watanabe et al.,
1985; Blakeslee et al., 1987; Koralnik et al., 1994).
The different transmission modes of HTLV-1 have been rapidly
studied by the same groups (Kinoshita et al., 1984; Okochi et al.,
1984; Hino et al., 1985; Kajiyama et al., 1986; Murphy et al., 1989;
Takahashi et al., 1991; Hino, 2011). They are now rather well
understood. This led to some efficient preventive measures in sev-
eral countries (Ando et al., 1987; Hino et al., 1987; Inaba et al.,
1989).
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In contrast, the world distribution and the global and
loco-regional estimation of the HTLV-1 prevalence remain yet
poorly known. This lack of knowledge is mainly due to four
different factors: (1) Several large regions/areas have not been
investigated for HTLV-1 infection. Thus, the prevalence remains
barely unknown in many areas of the world. This is evident in
some highly populated regions of Asia or in East and North Africa.
(2) The assays used for HTLV-1 serology exhibited some lack of
specificity leading in the 1980s–1990s to an overestimated HTLV-
1 prevalence. (3) Most of the works performed to appreciate the
HTLV-1 prevalence are based on study of series of blood donors,
pregnant women, or hospitalized patients. Population-based stud-
ies trying to estimate HTLV-1 prevalence in large areas, or even
at a country level, remain very rare. (4) A very important last
point is that, in most of the studied areas, HTLV-1 distribution is
not homogeneous. HTLV-1 is indeed present mainly as relatively
small foci or clusters with a high or very high prevalence of infec-
tion, with nearby quite low endemic areas. This has been very well
exemplified in Southern Japan and in some areas of South Amer-
ica. Thus, to give a precise estimation of HTLV-1 prevalence in a
specific country or area is relatively difficult and, in some cases,
nearly impossible.
Very few studies have thus given an estimation of the HTLV-
1 world prevalence. Japan and the African continent have been
rapidly considered, as the two regions in which HTLV-1 infected
persons were the most numerous. Then, South America has
also been considered as a very important focus of HTLV-1
carriers and associated diseases (mainly ATL or tropical spas-
tic paraparesis/HTLV-1 associated myelopathy (TSP/HAM), a
chronic severe neuromyelopathy). One of the most frequently
quoted estimation number of infected persons is based on a
paper, published in 1993 by G. de Thé and R. Bomford from our
group in Pasteur (de The and Bomford, 1993). This study gave a
rough estimation of 10–20 millions of HTLV-1 infected individ-
uals worldwide. In most of the review published since then, this
number is often taken as a fact (Proietti et al., 2005; Verdonck et al.,
2007; Hlela et al., 2009; Watanabe, 2011).
By writing this paper, our main goal was to revisit the situation
of HTLV-1 epidemiology, especially its world distribution, and
its estimated prevalence. This will be based on the current data,
available in 2012, thus around 30 years after the first published epi-
demiological studies and nearly 20 years after the last estimation
of global HTLV-1 prevalence.
This ambitious work has been based on the analyses of: (1)
most of the 1,100 papers referenced in PubMed on such a topic,
(2) most of the available book chapters concerning HTLV-1 epi-
demiology but also (3) on all the abstracts (of the epidemiology
sections) of the International Conference on HTLV and related
viruses held since 1985.
This study was, of course, possible thanks to our expertise and
experience in the field since 30 years for one of us and nearly
10 years for the other one.
After presenting the different methods used for the epidemi-
ological studies of HTLV-1 infection, we shall describe briefly
the major epidemiological determinants and the different trans-
mission modes of this human retroviral infection. Then, a small
chapter will report the major findings concerning the molecular
epidemiology of HTLV-1, which possesses an unusual great genetic
stability for a retrovirus. Lastly, we shall try to present, with a table
and a map, the HTLV-1 worldwide distribution and its prevalence
estimates by continent and by country when possible.
METHODS FOR HTLV-1 EPIDEMIOLOGY
Most of the studies were performed on series of blood
donors, pregnant women, or hospitalized patients. In few cases,
population-based studies were done in some villages, towns, or
even regions of a given country. The epidemiological and demo-
graphic characteristics of blood donors could be very different
according to the countries: indeed, they can be quite represen-
tative of the middle-class population in some countries but in
other areas, either they are mainly family members of hospitalized
patients, or they originate from low socio-economic populations
and are sometimes paid to give blood and, lastly, in several areas
(especially in some African studies) they are mainly young men.
HTLV-1 prevalence varies according to age, sex, and economic level
in most of HTLV-1 endemic areas. Thus, the prevalence found in
blood donors can be, of course, useful, but provides not always
the best data to estimate precisely the HTLV-1 prevalence in a
given country. The real prevalence is very probably higher than
that found in blood donors in most of the cases. Thus, the data
based on pregnant women are generally more useful to compare
the situation between different areas or countries as first, it is quite
representative of a given region and second, the mean age of preg-
nant women is generally comparable (about 22–26 years) in most
of the countries. The studies in general populations, in or out-adult
patients, can also be very useful to try to appreciate the HTLV-
1 prevalence in a given area as, in the great majority, the tested
patients do not suffer of the very rare diseases linked specifically
to HTLV-1 infection.
Diagnostic methods used for the study of HTLV-1 infection
include mainly serological assays searching for antibodies directed
specifically against different HTLV-1 antigens. Screening tests
are usually Enzyme-Linked Immunoabsorbent Assay (ELISA) or
Particle Agglutination (PA). Confirmatory tests are immunoflu-
orescence (IFA), but mostly Western Blot (WB), or Innogenetics
line immunoassay (INNO-LIA). Moreover, research of integrated
provirus, in the DNA from peripheral blood cells, could be done by
qualitative and/or quantitative polymerase chain reaction (PCR).
Despite some improvements in the WB assays specificity during
the last two decades, indeterminate serological patterns remain
frequent following WB analysis, and represent an important con-
cern for routine screening in blood banks in Europe, the Americas,
and some parts of Africa. It is also of course a major issue for
comparative analyses between epidemiological studies performed
in both low and high endemic areas, especially in intertropical
areas (Mauclere et al., 1997; Filippone et al., 2012). The signif-
icance of these frequent indeterminate WB can be various but,
in the majority of the cases, remains mostly unknown and a
matter of debate reviewed in Filippone et al. (2012). Indeed, in
rare cases, these patterns have been associated to (i) HTLV-1 but
mostly HTLV-2 infection exhibiting an atypical HTLV-serology,
(ii) HTLV-1 seroconversion, (iii) infection by a different retrovirus
such as the recently discovered HTLV-3 or HTLV-4 (Mahieux and
Gessain, 2009). Furthermore, some have been considered as the
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results of cross-reactivity against other microbial agents, especially
Plasmodium falciparum in Central Africa and Indonesia (Porter
et al., 1995; Mahieux et al., 2000). In this review, we shall take into
account, in the great majority, only the studies in which HTLV-1
infection has been confirmed by a specific test, mostly a WB.
MAJOR EPIDEMIOLOGICAL DETERMINANTS OF HTLV-1
HTLV-1 is not an ubiquitous virus. Indeed, it is present throughout
the world, with clusters of high endemicity located often nearby
areas where the virus is nearly absent. In these foci, the HTLV-1
seroprevalence in adults is estimated to be at least 1–2% but it can
also reach 20–40% in persons older that 50 years in some specific
clusters. The main very highly endemic areas are the Southwestern
part of Japan, some parts of the Caribbean area, and its surround-
ings regions, foci in South America including especially parts of
Colombia and French Guyana, some areas of intertropical Africa
(such as South Gabon) and of the middle East (such as the Mashad
region in Iran), and rare isolated clusters in Australo-Melanesia.
In Europe, only Romania seems to represent an HTLV-1 endemic
region. The origin of this puzzling geographical or rather eth-
nic repartition is not well understood but is probably linked to
a founder effect in some groups, followed by the persistence of a
high viral transmission rate.
Interestingly and despite different socio-economic and cultural
environments, HTLV-1 seroprevalence increases gradually with
age, especially in women, in all the highly endemic areas. The
general increase with age may be related to a cohort effect, as well
as demonstrated in Japan, while the increase in women might also
be due to an accumulation of sexual exposures with age (Blattner
et al., 1986; Chavance et al., 1989; Ueda et al., 1989; Mueller, 1991;
Murphy et al., 1991).
Three modes of transmission have been demonstrated for
HTLV-1. (1) Mother to child transmission, which is mainly linked
to a prolonged breast-feeding after 6 months of age (Hino, 2011).
Ten to 25% of the breast-fed children born from HTLV-1 infected
mothers will become infected. High level of HTLV-1 proviral load
in milk, in blood cells as well as high HTLV-1 antibody titers in the
serum, and long duration of breast-feeding (at least >6 months)
represent major risk factors for HTLV-1 transmission from mother
to child (Takahashi et al., 1991; Hino et al., 1994; Ureta-Vidal
et al., 1999; Li et al., 2004). (2) Sexual transmission, which mainly,
but not exclusively, occurs from male to female, and is thought
to be responsible for the increased seroprevalence with age in
women (Murphy et al., 1989; Stuver et al., 1993; Takezaki et al.,
1995; Kaplan et al., 1996; Roucoux et al., 2005). (3) Transmission
with contaminated blood products (containing HTLV-1 infected
lymphocytes), which is responsible for an acquired HTLV-1 infec-
tion among a high proportion (15–60%) of the blood recipients
(Okochi et al., 1984; Inaba et al., 1989). HTLV-1 infection is also
present among intravenous drug users but at a lesser extent than
HTLV-2 (Murphy et al., 1999).
HTLV-1 MOLECULAR EPIDEMIOLOGY: PRESENCE OF
GEOGRAPHICAL/ETHNIC RELATED SUBTYPES/GENOTYPES
On a molecular point of view, HTLV-1 possesses a remarkable
genetic stability, an unusual feature for a retrovirus. Viral amplifi-
cation via clonal expansion of infected cells, rather than by reverse
transcription is, very probably, the reason for this striking genetic
stability. The low sequence variation of HTLV-1 can be used as a
molecular tool to follow the migrations of infected populations
in the recent or distant past and thus to gain new insights into
the origin, evolution, and modes of dissemination of such retro-
viruses and of their hosts (Gessain et al., 1992b; Yanagihara, 1994).
The few nucleotide substitutions observed among virus strains
are indeed specific to the geographic origin of the patients rather
than the pathology. Four major geographic subtypes (genotypes)
have been reported. They include the Cosmopolitan subtype A,
the Central African subtype B, the Central African/Pygmies sub-
type D, and the Australo-Melanesian subtype C. A limited number
of strains found in Central Africa belong to other rare subtypes
(E, F, G). The Cosmopolitan subtype A, which comprised several
geographical subgroups (Japanese, West Africa, North African. . .)
is the most widespread, being endemic in Japan, the Caribbean
area, Central and South America, North and West Africa as well
as part of the Middle East. The sequence variability within sub-
type A is very low. This is very likely to reflect a relatively recent
dissemination (some centuries to few millenium) of this geno-
type from a common ancestor. The Australo-Melanesian subtype
C is the most divergent. This result reflects a long period of
evolution (at least several millenium) in isolated populations liv-
ing in different islands of the Pacific area. The appearance of
these HTLV-1 subtypes in humans was strongly suggested to
be linked to interspecies transmission between STLV-1 infected
monkeys and humans, followed by variable period of evolution
in the human host (Salemi et al., 1998; Vandamme et al., 1998;
Meertens et al., 2001; Nerrienet et al., 2001; Wolfe et al., 2005).
Indeed, STLV-1, the simian counterpart of HTLV-1, infects several
species of non-human primates (NHPs) of the Old Word, rang-
ing from chimpanzees, orangutans, and gorillas to mandrills, as
well as several African small monkey species and a wide range
of macaques, and other Asian monkeys. Interestingly, STLV-1
infection was also associated to the development of ATL in some
NHPs.
A map of the different HTLV-1 molecular subtypes and
places of possible interspecies transmissions from STLV-1 infected
monkeys to humans is presented on Figure 1.
There is so far no solid evidence that either a particular specific
mutation or a genotype is associated with the development of a
TSP/HAM or an ATL, in an asymptomatic carrier. Data concern-
ing level of transmission or proviral load according to molecular
subtypes need to be performed.
HTLV-1 WORLDWIDE DISTRIBUTION AND PREVALENCE
ESTIMATES BY GEOGRAPHICAL AREA
To give a general overview of the HTLV-1 worldwide distribution
was relatively easy for most of the regions. However, to try to pro-
vide an estimate, even rough, of the number of HTLV-1 infected
persons in the different world areas, even in well-studied high
HTLV-1 endemic regions was not at all an easy task. In all the cases,
such estimates must be absolutely taken with cautious. Indeed,
as said above, very few large population-based studies have been
done and most of the analyzed studies concern mainly blood
donors, pregnant women, or populations of different in or out-
adult patients not really representative of the population of a given
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FIGURE 1 | Map of the geographical distribution of HTLV-1 subtypes
(A–G), and the main modes of viral dissemination by movements of
infected populations. Small arrows indicate the very probable inter-
species transmission of STLV-1 (S) from monkeys to Humans (H) at the
origin of some current HTLV-1 subtypes. These different subtypes
comprise the Cosmopolitan A subtype with its different subgroups: TC
(Transcontinental being the most frequent and widespread one), Awa
(West African), Ana (North African), Ajp (Japanese), B or Central African
being the most frequent in this large endemic area, C or Australo-
Melanesian D, also from Central Africa and present especially in certain
Pygmy groups and lastly E, F, G with very few strains yet reported (all in
Central Africa). The main HTLV-1 molecular epidemiological studies used to
draw this map are the following ones: (Gessain et al., 1991; Gasmi et al.,
1994; Miura et al., 1994; Mahieux et al., 1997, 1998; Salemi et al., 1998;
Vandamme et al., 1998; Wolfe et al., 2005; Cassar et al., 2007; Gessain,
2011).
area or country on an epidemiological point of view (Table 1 and
Figure 2).
HTLV-1 IN EUROPE
Europe represents around 400 millions of persons. Numerous
epidemiological studies have been performed in this continent,
mainly in blood donors and in pregnant women (Courtois et al.,
1990; Courouce et al., 1993; Nightingale et al., 1993; Zaaijer et al.,
1994; Dalekos et al., 1995; Ferrante et al., 1997; Hale et al., 1997;
Tuset et al.,1997; Poljak et al.,1998;Ades et al.,2000; Machuca et al.,
2000; Tseliou et al., 2004, 2006; Vrielink and Reesink, 2004; Taylor
et al., 2005; Davidson et al., 2006; Laperche et al., 2009; Brant et al.,
2011). Furthermore, several large series of ATL and TSP/HAM
have been reported (Gout et al., 1989; Rio et al., 1990; Plumelle
et al., 1993; Martin et al., 2010; Ceesay et al., 2012). The most
studied countries are the United Kingdom (UK), Metropolitan
France, and Spain. Based on all these works, it is now clear that
most (at least more than 80%) of the persons infected by HTLV-
1 living currently in Europe originate directly, or are children or
descendents of immigrants, from a high endemic area, mostly West
Indies and Africa. Thus, in UK, most of HTLV-1 carriers origi-
nate from the former British West Indies, especially Jamaica and
also, at a lesser extent, Barbados, Trinidad, and Tobago (Catovsky
et al., 1982; Payne et al., 2004; Dougan et al., 2005). More rarely,
they originate from West Africa as Ghana or Sierra Leone. Con-
cerning Metropolitan France, most of the persons originate from
French West Indies as Martinique or Guadeloupe (Gout et al.,
1989; Gessain et al., 1990c; Rio et al., 1990; Plumelle et al., 1993).
They can also originate from West or Central Africa as Sene-
gal, Mali, Guinea, Côte d’Ivoire, or Cameroon (Gessain et al.,
1990b, 1992a; Rio et al., 1990; Mahe et al., 1994; Duval et al.,
2010). It is important to note that in blood donors and, thus,
very probably in the general population, a certain proportion
of infected persons are women, of Caucasian background, that
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Table 1 | HTLV-1 seroprevalence among pregnant women originating from HTLV-1 endemic countries in Africa,West Indies, North and South
America, Asia, and Europe.
Region Country HTLV-1 seropositive
women (%)
Reference
AFRICA Guinea-Bissau 2.2 (27/1,231) Andersson et al. (1997)
Côte d’Ivoire 1.9 (10/513) Verdier et al. (1989)
Ghana 2.1 (20/960) Armah et al. (2006)
Burkina-Faso 1 (5/492) Collenberg et al. (2006)
Nigeria 5.5 (20/364) Olaleye et al. (1995)
Gabon 2.1 (19/907) Etenna et al. (2008)
Zaire 4.6 (19/414) Goubau et al. (1993)
Zaire 3.7 (43/1,166) Delaporte et al. (1995)
Congo 0.7 (14/2,070) Tuppin et al. (1996)
South Africa 0.2 (1/428) Goubau et al. (1993)
WEST INDIES Martinique 2.4 (17/716) Denis et al. (1988)
Martinique 1.9 (9/467) Mansuy et al. (1999)
Jamaica 3.5 (81/2,329) Wiktor et al. (1993)
Jamaica 3.8 (350/9,226) Maloney et al. (2006)
Haiti 2.2 (11/500) Allain et al. (1992)
Haiti 4.2 (12/287) Tortevoye et al. (2005)
NORTH AMERICA Mexico (Yucatan) 0 (0/590) Gongora-Biachi et al. (1996)
ASIA India (Vellore) 0 (0/201) Ramalingam et al. (2001)
Japan (Honshu) 0.6 (14/2,414) Goto et al. (1997)
Japan (Nagasaki and Kyushu) 3.7 (187/5,015) Hino et al. (1985)
Japan (whole Kyushu) 5.4 (885/16,283) Oki et al. (1992)
Japan (Kagoshima in Kyushu) 5.8 (138/2,374) Umemoto et al. (1994)
Japan (Okinawa) 3.9 (670/17,207) Maehama (2004)
EUROPE United Kingdom 0.04 (52/126,010)* Ades et al. (2000)
United Kingdom 0.03 (23/69,013)◦ Ades et al. (2000)
France 0.1 (12/10,398) Courtois et al. (1990)
Italy 0.02 (1/6,000)* Taylor et al. (2005)
Spain 0.01 (2/20,366)* Machuca et al. (2000)
Slovenia 0.01 (1/10,369) Poljak et al. (1998)
Greece 0 (0/2,016) Tseliou et al. (2006)
SOUTH AMERICA French Guyana (Noir Marron population) 5.7 (70/1,225) Carles et al. (2004)
French Guyana (Noir Marron population) 4.2 (181/4,266) Tortevoye et al. (2005)
Brazil (Mato Grosso) 0.2 (7/2,965) Ydy et al. (2009)
Brazil (Mato Grosso South) 0.1 (37/32,512) Figueiro-Filho et al. (2007)
Brazil (Salvador Bahia) 0.8 (57/6,754) Bittencourt et al. (2001)
Brazil (Sao Paulo) 0.1 (1/913) Olbrich Neto and Meira (2004)
Brazil (Sao Luis) 0.2 (4/2,044) Guimaraes de Souza et al. (2012)
Peru (Andes,Coast,Jungle,Lima) 1.3 (32/2,492) Alarcon et al. (2006)
Peru (Quechua population) 2.4 (5/211) Zurita et al. (1997)
Argentina (Cordoba-Central) 0.1 (3/3,143) Trenchi et al. (2007)
The quoted studies are, to our knowledge, among the most representative and reliable ones to date.
*including black African and Afro-Caribbean women.
◦Women born exclusively in the United Kingdom.
have acquired HTLV-1 through sexual contacts with a partner
originating from an HTLV-1 endemic area. This situation can rep-
resent around 5–10% in different European countries including
France or UK (Dougan et al., 2005). In Spain, the situation is
slightly different as, due to historical reasons, most of the HTLV-
1 infected persons are from South America (Toro et al., 2002;
Padua et al., 2011; Trevino et al., 2012). However the prevalence
seems much lower than in UK or in Metropolitan France. In
Portugal, this is about the same but, in some cases, the HTLV-
1 infected persons can originate from ancient African colonies
such as Mozambique and Angola (Padua et al., 2011). Intra-
venous drug users represent also a population relatively endemic
for HTLV-1, specially in Spain, Italy, and Ireland even if HTLV-
2 is always much more prevalent in such a specific population
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FIGURE 2 | Geographical distribution of the main foci of HTLV-1
infection. Estimates of the number of HTLV-1 infected carriers, based on
approximately 1.5 billion of individuals from known endemic areas and
reliable epidemiological data obtained from studies among pregnant
women and/or blood donors and/or different adult populations. In few
countries, HTLV-1 endemic areas are limited to residents of certain regions
such as Mashad in Iran, The Fujian Province in China, Tumaco in Colombia
and Central Australia.
(Gradilone et al., 1986; Calderon et al., 1995; Chironna et al.,
1996).
The level of HTLV-1 infection in most of the other European
countries is very low as demonstrated by an HTLV-1 prevalence
in first-time blood donors of less than 0.4/10,000 and a great rar-
ity of ATL or TSP/HAM reports (Laperche et al., 2009). The only
exception seems to be Romania, which appears to be the only
true HTLV-1 endemic area in Europe (Paun et al., 1994; Veelken
et al., 1996). Indeed, a prevalence of 5.3/10,000 donations has been
recently reported among first-time blood donors in this East Euro-
pean country (population of 22 millions; Laperche et al., 2009).
HTLV-1 infection in polytransfused patients is also quite high
ranging from 3 to 25%. Furthermore, series of cases of ATL or
TSP/HAM have been reported in Romania. Lastly, sporadic cases
have also been seen in immigrants from this country living in other
European countries (Veelken et al., 1996; Manca et al., 1997). These
data, taken together, demonstrate clearly a relatively high level of
HTLV-1 infection in this country. The origin of such situation
remains unknown and the matter of different hypotheses.
The estimation of the number of HTLV-1 infected persons in
Europe is a very difficult exercise. Based on all data from UK
and especially their numerous studies, the team of Graham Taylor
suggests that 20,000–30,000 people have HTLV-1 infection in the
UK (Ades et al., 2000). Concerning Metropolitan France, based
on the study on prevalence in blood donors, pregnant women,
and the incidence of ATL cases, we can estimate that it is roughly
equivalent with around 10,000–25,000 HTLV-1 infected persons.
Importantly and, as in the UK, most of them are undiagnosed.
Concerning Romania, this is more difficult, due to the few available
studies. However, in a recent study, the prevalence in the first-time
blood donors seems 10 times more in Romania than in UK and
Metropolitan France (Laperche et al., 2009). A rough minimal esti-
mation of few thousands with a wide range (3,000–15,000) can be
proposed. However, we cannot rule out the presence of possible
HTLV-1 clusters, or foci, in some specific areas or populations in
such country.
HTLV-1 IN AFRICA
The total population of Africa is estimated at a little more than 1
billion in 2012. The African population has grown a lot over the
past century. Indeed, the population doubled for the period 1982–
2009 and quadrupled during the years 1955–2009. Thus, more
than 40% of the population is below 15 years old in most sub-
Saharan countries. Africa is probably the largest endemic area for
HTLV-1. However, despite numerous epidemiological studies and
reports of sporadic cases or even small series of ATL and TSP/HAM
cases, the situation concerning the level of HTLV-1 infection, is
not really known in several countries and regions of this large
continent. Indeed, very few large studies on representative general
population are available.
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Here, we shall first briefly report the situation, based on the
most solid studies (large populations of mainly blood donors,
pregnant women, or adult hospitalized patients or control groups,
and robust serological tests including mainly a WB for confir-
mation), according to five large geo-climatological areas: North
Africa, West Africa, Central Africa, East Africa, and lastly South
Africa. Then, we shall try to estimate the number of HTLV-1
infected persons in some specific countries for which reliable data
are available.
North Africa/Maghreb
The very few studies concern mainly blood donors or multi-
transfused patients from Egypt, Morocco, and Tunisia where
the HTLV-1 seroprevalence appears to be very low or negative
(Saxinger et al., 1984; de-The et al., 1985; de The and Gessain,
1986; El-ghazzawi et al., 1987; el-Farrash et al., 1988; van Doornum
et al., 1990; Mojaat et al., 1999; Kawashti et al., 2005; Stienlauf et al.,
2009). Very few cases of ATL or TSP/HAM have been reported in
such countries, including at least Morocco and Egypt, either diag-
nosed locally or in immigrants, especially in France (Thyss et al.,
1990; Gasmi et al., 1994; Gharibi et al., 2011). In summary, based
on the scarce available data, Morocco seems to be, in North Africa,
the only country that can be considered as HTLV-1 endemic, how-
ever at a low level and a reliable estimation of the number of
HTLV-1 infected persons in North Africa is currently impossible.
West Africa
This large area comprises 16 countries: Benin, Burkina-Faso, Cape
Verde, Côte d’Ivoire, Gambia, Ghana, Guinea and Guinea-Bissau,
Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone,
and Togo. This represents more than 300 millions of inhabitants.
Several large studies have been performed in Senegal, Guinea-
Bissau, Côte d’Ivoire, Ghana, and Nigeria. Furthermore, ATL
and/or TSP/HAM have been reported in most of these countries
including especially Senegal, Mauritania, Mali, Côte d’Ivoire, Nige-
ria (Fleming et al., 1986; Gessain et al., 1990a,c; Williams et al.,
1993, 1994; Mahe et al., 1994; Michel et al., 1996; Analo et al.,
1998; Fouchard et al., 1998; Sene-Diouf et al., 2000). The HTLV-1
seroprevalence in blood donors ranged mainly from 0.2 to 3%.
However, in most of these studies, blood donors are mainly young
men. In Senegal, based on a study of 4,900 blood donors, HTLV-1
seroprevalence was of 0.16%, however most of the infected donors
originated from the South of the country, where the prevalence
reached 1% (Diop et al., 2006). In Guinea, it was of 1.2% (22/1,785;
Gessain et al., 1993a), while in Côte d’Ivoire and Ghana it ranges
from 0.5 to 2% depending on the studies (Ouattara et al., 1989;
Verdier et al., 1989; Biggar et al., 1993; Sarkodie et al., 2001; Ampofo
et al., 2002; Armah et al., 2006). In Nigeria, it varies from 0.7 to
3.7% according to geographical location (Fleming et al., 1986;
Analo et al., 1998). Other studies were performed on pregnant
women or representative general adult population or on different
control groups. The HTLV-1 prevalence was around 1% in Guinea,
with variations from 0.2 to 1.9% depending on the region (Jean-
nel et al., 1995), and ranged from 2.2 to 3.6% in Guinea-Bissau
(Andersson et al., 1997; Larsen et al., 2000; da Silva et al., 2009). It
was of 1.2% in Gambia (Del Mistro et al., 1994) and ranged from
0.2 to 1.2% in Senegal (Hunsmann et al., 1984). It was of 1% in
Burkina-Faso (Collenberg et al., 2006) and ranged from 1 to 1.6%
in Liberia, Togo and Benin (Hunsmann et al., 1984; Dumas et al.,
1991; Verdier et al., 1994; Houinato et al., 1996), and from 1 to
2.7% in Côte d’Ivoire and Ghana according to the type of stud-
ies (Ouattara et al., 1989; Verdier et al., 1989, 1994; Biggar et al.,
1993; Goubau et al., 1993; Armah et al., 2006) and reached 5.5% in
Nigeria (Olaleye et al., 1994, 1995). The estimates of the number
of HTLV-1 infected persons in most of the West African countries
are given in Table 2.
Central Africa
This area comprises nine countries including, Angola, Cameroon,
Central African Republic (CAR), Chad, Democratic Republic of
the Congo (DRC) formerly Republic of Zaire, Equatorial Guinea,
Gabon, Republic of the Congo, Sao-Tome-et-Principe. This repre-
sents around 130 millions of persons. Several important epidemio-
logical studies have been performed in Cameroon and especially in
Gabon. Cases of ATL and/or TSP/HAM have been reported mainly
in Cameroon, Gabon and the DRC (Kayembe et al., 1990; Jean-
nel et al., 1993). HTLV-1 prevalence in adults living in Cameroon
ranges globally from 0.5 to 2% depending on the geographical
location, the studied population, and the ethnic group (Mauclere
et al., 1997; Mauclère et al., 2011; Filippone et al., 2012). Indeed,
the Pygmies groups, who live mainly in the Southern region of this
country, have a much higher level of HTLV-1 prevalence (around
of 2–10% in adults depending on age) than the Bantu groups
(around 0.3–1.5%), who represent most of the population of this
area (Mauclere et al., 1997; Mauclère et al., 2011; Filippone et al.,
2012). In Gabon, several studies of different representative urban
or rural populations have been performed (Delaporte et al., 1988,
1991; Bertherat et al., 1998). This is the best-studied country for
Africa concerning the HTLV-1 infection. All the data indicated a
global high HTLV-1 seroprevalence of around 5–10% in the adult
populations (Delaporte et al., 1988, 1991; Bertherat et al., 1998).
In pregnant women it ranged from 1 to 5% according to the geo-
graphical location (Schrijvers et al., 1991; Etenna et al., 2008).
Based on several studies, it appears clearly that the Haut-Ogoué
region (a Southeastern area of the country) is the highest endemic
area of Gabon for HTLV-1 infection. Indeed, in some villages of
this region, the HTLV-1 seroprevalence can reach more than 25%
in elder adults, especially women (Delaporte et al., 1989b; Le Hes-
ran et al., 1994). This area represents very probably the highest yet
known HTLV-1 endemic area in the African continent. In CAR,
HTLV-1 infection has been reported in Pygmies from the South-
ern region (Gessain et al., 1993b) and a seroprevalence of 7% has
been recently shown in aged adults (>55 years old) of the same
rain forest area (Pepin et al., 2010). In the Republic of the Congo
and in DRC, HTLV-1 prevalence in pregnant women ranged from
0.7 to 3.7% depending on the studies (Delaporte et al., 1995; Tup-
pin et al., 1996). Furthermore, several other reports from DRC
indicated that a relatively high HTLV-1 prevalence (5 to more
than 20%) in different adult populations including hospitalized
patients, prostitutes, leprosy patients (Kayembe et al., 1990; Wiktor
et al., 1990; Delaporte et al., 1995; Lechat et al., 1997). Such results
depended widely on the geographical areas of the tested persons
with high prevalence region (as the Haut-Zaire/Equateur) and low
prevalence ones (Goubau et al., 1993; Delaporte et al., 1995). The
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Table 2 | Estimates of the number of HTLV-1 infected carriers, based on
approximately 1.5 billion of individuals from known HTLV-1 endemic
areas and reliable epidemiological data obtained from studies
performed among pregnant women and/or blood donors and/or
different adult populations.
Continent/
Country
Population! HTLV-1 range
AFRICA
Senegal 12,969,606 30,000 105,000
Gambia 1,840,454 2,500 13,000
Guinea-Bissau 1,628,603 12,000 28,000
Guinea 10,884,958 75,000 150,000
Sierra Leone/
Liberia
5,485,998/3,887,886 50,000 100,000
Côte d’Ivoire 21,952,093 130,000 250,000
Ghana 25,241,998 125,000 375,000
Togo/Benin 6,961,049/9,598,787 80,000 160,000
Burkina Fasso 17,275,115 42,000 125,000
Mali 14,533,511 32,000 95,000
Nigeria 170,123,740 850,000 1,700,000
Cameroon 20,129,878 80,000 180,000
Eq. Guinea 685,991 1,500 4,500
Gabon 1,608,321 16,000 30,000
CAR 5,057,208 15,000 30,000
DRC 73,599,190 600,000 1,300,000
Republic of
The Congo
4,366,266 12,000 36,000
Mozambique 23,515,934 120,000 360,000
South Africa 48,810,427 180,000 540,000
ASIA
China (Fujian
Province)
35,110,000 2,000 20,000
Japan* 127,368,088 1,080,000 1,300,000
Iran (Mashad
area)
78,868,711 10,000 40,000
Taiwan 23,113,901 10,000 30,000
EUROPE
United
Kingdom**
63,047,162 20,000 30,000
France 65,630,692 15,000 25,000
Spain 47,042,984 1,000 8,000
Romania 21,848,504 3,000 15,000
CARIBBEAN REGION
Haiti/Dominican
Republic
9,801,664/10,088,598 150,000 350,000
Jamaica 2,889,187 100,000 140,000
Guadeloupe# 401,730 3,000 6,000
Martinique# 395,953 3,000 6,000
Trindad and
Tobago
1,226,383 9,000 18,000
NORTHAMERICA
United States 313,847,465 90,000 100,000
CENTRALAND SOUTHAMERICA
Panama 3,510,045 3,500 25,000
(Continued)
Table 2 | Continued
Continent/
Country
Population! HTLV-1 range
Colombia
(Tumaco area)
45,594 (est.1988) 1,000 1,500
Venezuela 28,047,938 14,000 70,000
Suriname 560,157 3,000 7,000
French Guyana 217,000 2,000 5,000
Guyana 741,908 2,000 5,000
Peru 29,549,517 150,000 450,000
Brazil 205,716,890 300,000 800,000
Chile 17,067,369 90,000 250,000
AUSTRALO-MELANESIA
Australia
(Aboriginal
Australians)
463,900 2,500 5,000
Solomon
Islands
584,578 3,000 6,000
Vanuatu 227,574 250 1,000
Total 1,567,570,505 4,520,250 9,295,000
The HTLV-1 ranges were estimated combining the prevalence rates deduced from
the above studied populations and the global repartition of individuals by age and
sex in each studied country. In some highly populated countries and regions,
such as China, India, the Maghreb and East Africa, correct estimates are cur-
rently not possible.Thus, the current total number of HTLV-1 carriers in the world
is very probably much higher. Eq. Guinea, Equatorial Guinea; CAR, Central African
Republic.
!According to the CIAWorld Factbook 2012 estimations (www.cia.gov).
*According to Satake et al. (2012).
**According to Brant et al. (2011).
#According to the National Institute of Statistics and Economic Studies 2011
estimations (www.insee.fr).
prevalence of HTLV-1 in Chad seems quite lower (around 0.5–
1% in adults in the Southern part). The situation in Angola is
less known. The estimates of the number of HTLV-1 infected per-
sons in Cameroon, Gabon, Equatorial Guinea, CAR, DRC and the
Republic of The Congo are given in Table 2.
East Africa
This large area comprises 12 countries including: Burundi, Ery-
threa, Ethiopia, Kenya, Malawi, Mozambique, Rwanda, Somalia,
Tanzania, Uganda, Zambia, and Zimbabwe. Relatively few studies
on HTLV-1 infection (with the exception of Mozambique) have
been performed in such a large and highly populated region (total
of more than 330 millions of inhabitants). Moreover, only spo-
radic cases of ATL and/or TSP/HAM have been reported from
East African countries. Lastly, this region appears globally much
less endemic for HTLV-1 than West and Central Africa. The rea-
sons of such a situation are unknown. Indeed, all the studies
performed in the countries, North of Malawi, indicate a very
low or an absence of HTLV-1 infection. As examples, a nation-
wide community-based survey performed in Rwanda on more
than 2,500 samples indicated an HTLV-1 seroprevalence of 0.2%
(Group, 1989), and in Zimbabwe, only one blood donor out of 931
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(0.1%) was found HTLV-1 seropositive (Houston et al., 1994). The
situation in Mozambique (a country of 24 millions) appears dif-
ferent. Indeed, a study on 2,019 blood donors from Maputo city
reported an HTLV-1 seroprevalence of 0.9% (Gudo et al., 2009).
Another study in blood donors found an HTLV-1 seroprevalence
rate, among 15- to 49-year-old men and women respectively of
0.9 and 1.2% (Cunha et al., 2007). A study on 752 individuals
attending public heath centers from different areas of this country
found a seroprevalence of 2.3% with geographical regional varia-
tion (Caterino-de-Araujo et al., 2010). Furthermore, some cases of
TSP/HAM have been reported in Mozambique (Engelbrecht et al.,
1999) and HTLV-1 infection has been seen at a rate of around
4% in HIV infected patients (Bhatt et al., 2009). The estimation
of the number of HTLV-1 infected persons can be done only for
Mozambique (Table 2).
South African region
This area comprises only three countries: Botswana, Namibia, and
South Africa. Several studies have been performed but concern
only South Africa, a country of 48 millions of inhabitants.
Indeed, several sporadic case or series of ATL, TSP/HAM, or
infective dermatitis have been reported in South African patients
(Bhigjee et al., 1990, 1993; Joubert et al., 1991; Jogessar et al.,
1992). Indeed, as soon as 1999, around 200 black patients with a
TSP/HAM have been seen in Durban. Furthermore, several studies
performed in blood donors indicated an HTLV-1 seroprevalence
ranging from 0 to 5% according to the type of tested population
(black, white, young men, geographical location. . .; Bhigjee et al.,
1993). A community-based seroprevalence survey done in adults
from Natal/KwaZulu found a seroprevalence of 2.6% (26/1,018;
Bhigjee et al., 1993). Similar results (0.5–3%) have been found in
adults in other districts of this state and other states of the country
(Bhigjee et al., 1994; Taylor et al., 1996; van der Ryst et al., 1996).
The estimate of the number of HTLV-1 carriers in South Africa is
given on Table 2.
Concerning the islands of the Indian Ocean, very few data
are available. The situation is barely unknown in Madagascar,
Comoros, and Mauritius but, to our knowledge, no case of ATL
or TSP/HAM has been reported from these countries. It is dif-
ferent for the Reunion Island (an overseas French department
of approximately 800,000 inhabitants) and the Seychelles archi-
pelago. Indeed, in the Reunion Island, despite that few cases of
TSP/HAM and ATL have been reported (Cnudde et al., 1991;
Mahieux et al., 1994), a study on 3,900 blood donors (mostly
young adult males) indicated only one infected person (Mahieux
et al., 1994). By contrast, in the Seychelles, a cluster of TSP/HAM
cases has been described as well as an HTLV-1 seroprevalence of
3–5% in blood donors (Roman et al., 1987; Lavanchy et al., 1991).
HTLV-1 IN THE AMERICAS
North America
Most of the available studies on HTLV-1 prevalence in the United
States, concern blood donors and intravenous drug users. In one
of the first large study, nearly 40,000 blood donors in eight geo-
graphically diverse areas were screened for HTLV-1. Only 10 of
them (0.025%) showed evidence of HTLV-1 infection (Williams
et al., 1988). Seroprevalence rates ranged from 0 to 0.1% at the
locations sampled, with HTLV-1 antibodies found predominantly
in donors from the Southeastern and Southwestern United States.
The Retrovirus Epidemiology Donor Study group (REDS) evalu-
ated, during 1991–1995, the HTLV-1 prevalence among 1.7 million
donors from five REDS blood centers to 0.009% (Schreiber et al.,
1997). In 2001, another study reported that the HTLV-1 seropreva-
lence rate among 21,000 individuals representing various patient
populations including blood donors was 0.02% (Poiesz et al.,
2001). HTLV-1, but mostly HTLV-2, infections are highly endemic
among intravenous drug users in certain urban areas of the coun-
try (e.g., New Jersey), with seroprevalence rates reaching nearly
20% (Freeman et al., 1995). Among them,African-Americans were
significantly more likely than Hispanics and other racial groups to
be HTLV-1 positive (Lee et al., 1990; Cantor et al., 1991). The first
patient with ATL, initially thought to have a Sezary’s syndrome
and from whom HTLV-1 was first isolated, was described in 1980
in the United States (USl Poiesz et al., 1980). Typical ATL cases
were detected among US native-born patients (Blayney et al., 1983;
Dosik et al., 1988) and the first description of ATL in members of
a single family from the US occurred in 1988 (Denic et al., 1988).
Concerning TSP/HAM, small series of cases were published since
1988 (Bhagavati et al., 1988; Janssen et al., 1991). Later, larger series
of ATL and TSP/HAM cases have been described in the US and
most of the cases were identified in African-American individuals
from the Southeastern states such as Florida (Harrington et al.,
1995). A study estimates the number of HTLV-1 and 2 infected
persons at around 260,000 and that they are likely more than 3,600
people in the United States with unrecognized TSP/HAM (Orland
et al., 2003). It remains difficult to provide a solid estimate for
HTLV-1 in the USA (Table 2).
HTLV-1 seems to be rare in Canada and the number of HTLV-1
cases is unknown. Nevertheless, the HTLV-1 prevalence observed
among 168,668 blood donors in the Toronto region was 0.02
and 2.3% among regional individuals and people of Caribbean
origin respectively (Chiavetta et al., 1992). HTLV-1 infection
was also described in Amerindians from the coastal regions of
British Columbia (Dekaban et al., 1994; Picard et al., 1995; Peters
et al., 2000). Furthermore, some associated diseases (ATL and
TSP/HAM) were reported in coastal British Colombia Indians
(Power et al., 1989; Oger et al., 1993; Dekaban et al., 1994; Gascoyne
et al., 1996).
In Mexico, there is little information on HTLV-1 prevalence in
the general population despite the large population size of this
country which counts nearly 115 millions inhabitants. The few
studies are mainly conducted in the Yucatan peninsula or some
different states (Nuevo Leon in Northeast Mexico) and show the
absence of HTLV-1 infection among healthy women as well as in
blood donors (Gongora-Biachi et al., 1996, 1997; Trejo-Avila et al.,
1996).
Central America
Central America consists of seven states (Belize, Costa Rica, El Sal-
vador, Guatemala, Honduras, Nicaragua, and Panama). In 2012, its
estimated population is 42.6 millions. Despite the fact that some
of these countries have strong commercial and cultural ties with
the highly HTLV-1 endemic Caribbean Islands, relatively few stud-
ies concerning the HTLV-1 infection and the associated diseases
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have been performed except in the Honduras, Panama and, to a
lesser extent, in Costa Rica. In these countries, the HTLV-1 sero-
prevalence is rather low but with significant differences between
the populations tested. Thus, the HTLV-1 prevalence is signifi-
cantly higher in non-Mestizo population, especially individuals
living in the coastal cities of Honduras, than in the Mestizo ethnic
groups (8.1 versus 0.5% respectively; de Rivera et al., 1995). Addi-
tional studies showed an overall HTLV-1 prevalence of 0.3% in
the general Honduran population who live in central and North-
western part of the country (Segurado et al., 1997) and a higher
HTLV-1 prevalence in black natives individuals, without known
risk factors, but originating from cities located on the Atlantic
coast (Vallejo et al., 1996). In Panama, HTLV-1 seroprevalence
varied from 0.2 to 2% in the general adult population through-
out the country (Reeves et al., 1990). Few ATL or TSP/HAM cases
have been reported from Honduran native-born individuals (Tem-
ple et al., 1986) and in the Panamanian population (Levine et al.,
1989; Gracia et al., 1990).
The situation regarding HTLV-1 in Nicaragua and Costa Rica
is poorly known but rare studies revealed similar relatively low
HTLV-1 prevalence rates (0.2–0.7%), among the Nicaraguan and
Costa Rican adult populations (Khabbaz et al., 1990; Qiu et al.,
2008). In Belize, Guatemala and El Salvador, no HTLV-1 record
about the prevalence of the HTLV-1 infection has been published
to our knowledge.
South America
This area comprises 13 countries including Argentina, Bolivia,
Brazil, Chile, Colombia, Ecuador, French Guyana (an overseas
region of France), Guyana, Paraguay, Peru, Surinam, Uruguay,
and Venezuela. This represents around 400 millions of persons.
Numerous studies on HTLV-1 prevalence have been performed
in many of these countries, especially in Brazil, Peru, Columbia,
Chile, Argentina, and French Guyana. This vast continent repre-
sents, as a whole, a major endemic area for HTLV-1 infection and
associated diseases. Even more than in other world regions, it is
very difficult to appreciate the general HTLV-1 prevalence in a
given country, as specific high endemic foci have been frequently
reported in several South American countries. This is exemplified
in Peru, in some of the Quechua population groups, and also in
Columbia (Tumaco area) or in French Guyana (Noir-Marron pop-
ulation), where some specific groups of African origin are highly
endemic for HTLV-I infection and associated diseases.
In Peru, a real multiethnic country mainly inhabited by Mesti-
zos and Amerindians, HTLV-1 prevalence in blood donors ranges
from 1.2 to 1.7% depending on the region (Quispe et al., 2009) and
from 1.3 to 3.8% in pregnant women or in the adult general pop-
ulation (Zurita et al., 1997; Sanchez-Palacios et al., 2003; Alarcon
et al., 2006). Furthermore several large series of TSP/HAM and
ATL have been reported (Gotuzzo et al., 2004; Beltran et al., 2011).
However, as noted above, several studies have clearly demon-
strated that persons of Amerindians origin (Quechua speaking
groups), often living in isolated areas, are highly HTLV-1 endemic
(Fujiyoshi et al., 1999; Einsiedel et al., 2010).
In Chile, mainly populated by persons of Spanish ancestry
mixed with various Amerindian groups, the situation appears,
by certain aspects, roughly similar than in Peru. Indeed, HTLV-1
seems more endemic among indigenous people from isolated
Amerindians groups, living in the Andes, or in the most South-
ern region of the country, than in the general population. Studies
indicated an HTLV-1 seroprevalence ranging from 0.7 to 1.9% in
blood donors (Vasquez et al., 1991). Large series of TSP/HAM
(more than 200 cases seen before 1991) have been reported in
Chilean patients (Cartier et al., 1989, 1992) while ATL were more
rarely described (Cabrera et al., 1991).
In Columbia, several studies were focused on Tumaco, a densely
populated island of the Pacific lowland recognized as having a
very high prevalence of TSP/HAM (Arango et al., 1988; Zaninovic
et al., 1988). In the general population of this specific focus (mostly
inhabited by persons of African ancestry), the overall prevalence
rate of HTLV-1 was 2.8% and reached 5.3% in the adults (Trujillo
et al., 1992). Other reports indicated the presence of some foci of
HTLV-1 infection in different isolated Indian populations (Zani-
novic et al., 1994). Several ATL cases have also been described in
patients from Columbia (Blank et al., 1993).
In Venezuela, based on the few available data, the HTLV-1 sero-
prevalence seems quite low. Indeed, it was of 0.2% in a large series
of blood donors from Caracas (Leon et al., 2003). Furthermore,
only rare cases of TSP/HAM have been reported (Zabaleta et al.,
1994).
In Paraguay, HTLV-1 is rare and seems absent among the
Paraguayan general healthy population (Zoulek et al., 1992). In
Urugay, the seroprevalence reached 0.75% among the Urugayan
blood donors (Muchinik et al., 1992).
French Guiana has been extensively studied for HTLV-1 infec-
tion (Kazanji and Gessain, 2003). In this French overseas region,
HTLV-1 is mainly found in the Noir-Marron population, an eth-
nic group of African ancestry, also present currently in Surinam
(Tortevoye et al., 2000, 2005). Indeed, this population is highly
endemic for HTLV-1 (Plancoulaine et al., 1998; Carles et al., 2004)
and several ATL cases have been reported in this ethnic group
(Gerard et al., 1995). HTLV-1 infection and few associated dis-
eases have also been reported in Guyana, and Surinam mainly in
the persons of African ancestry (Pouliquen et al., 2004).
The numerous studies performed on blood donors and preg-
nant women from different areas of Argentina have revealed glob-
ally a low or very HTLV-1 seroprevalence, ranging roughly from
0.01 to 0.2% depending on the type and geographical location
of the tested populations (Gastaldello et al., 2004; Trenchi et al.,
2007; Berini et al., 2010). Some regions are thus considered as
non-endemic (as the central areas) in contrast to the Northeast-
ern provinces of the country (Biglione et al., 2005). In the same
line, relatively few cases of TSP/HAM and ATL have been reported
in this country (Biglione et al., 2003) ATL cases seems to be only
described in individuals of Caucasian origin (Gioseffi et al., 1995;
Marin et al., 2002).
Concerning Brazil, the situation is quite different and based on
a large amount of solid publications, we can consider without any
doubt that this country of more than 200 millions of inhabitants
represents one of the largest endemic area for HTLV-1 and asso-
ciated diseases. Indeed, several hundreds of cases of TSP/HAM,
ATL, as well as large series of infective dermatitis cases have been
reported in Brazilian patients (de Oliveira et al., 1990; Pombo
De Oliveira, 1996; Araujo et al., 1998; Bittencourt et al., 2009).
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Furthermore, several studies performed on large populations of
blood donors have found an heterogeneous HTLV-1 seropreva-
lence ranging from 0.04 to 1% depending on the geographical loca-
tion. The prevalence was higher in the North and Northeast than
in the South (Catalan-Soares et al., 2005). Another more recent
and large study show Brazilian blood donors prevalence of HTLV-
1 on the order of one per 1,000 with regional differences probably
due to the ethnic origin of the underlying population with indeed
a higher prevalence in donors with black skin color (2.14/1,000)
versus mixed (1.58/1,000) or white (0.79/1,000; Carneiro-Proietti
et al., 2012). Similarly, HTLV-1 prevalence in pregnant women
ranges from 0.1 to 0.8% depending on the tested area (Bitten-
court et al., 2001; Olbrich Neto and Meira, 2004; Figueiro-Filho
et al., 2007; Ydy et al., 2009; Guimaraes de Souza et al., 2012).
Interestingly, Salvador de Bahia, a large city of the eastern part of
the country, with a majority of inhabitants of African ancestry,
is considered as the Brazilian city with the highest global HTLV-1
prevalence (around 1.3% of blood donors, and 1.8% in the general
population; Galvao-Castro et al., 1997; Dourado et al., 2003).
HTLV-1 IN THE CARIBBEAN REGION
This region comprises more than 7,000 islands organized into 30
territories including sovereign states (e.g.,Cuba, Jamaica, Haiti and
Dominican Republic), overseas departments (e.g., Martinique,
Guadeloupe) and dependencies (e.g., Bermuda, Caiman Islands),
totalizing around 40 millions of inhabitants. The majority of
these islands have a relatively small population (few thousands
to half million persons). Only Cuba, Haiti/Dominican Republic,
and Jamaica have a population of more than two millions. All the
islands, which are mainly peopled with persons of African ances-
try, represent a high endemic region for HTLV-1 infection and
associated diseases.
Jamaica has been extensively studied concerning HTLV-1 infec-
tion (Clark et al., 1985; Murphy et al., 1991). Large series of ATL,
TSP/HAM, and infective dermatitis have been reported in this
island and in immigrants from Jamaica living, especially, in the
United Kingdom (Gibbs et al., 1984; Rodgers-Johnson et al., 1988;
Mowbray et al., 1989; La Grenade et al., 1990). In a large cohort
of 13,260 Jamaicans from all parts of the island, HTLV-1 sero-
prevalence was high (mean 6.1%) ranging from 1.7 to 17.4%,
depending on sex and age (Murphy et al., 1991). In pregnant
women and in blood donors, it was of around 2–3.8% (Wiktor
et al., 1993; Dowe et al., 1998; Brady-West and Buchner, 2000; Mal-
oney et al., 2006). The situation is less known but could be quite
similar in Haiti and the Dominican Republic. HTLV-1 seropreva-
lence in pregnant women is around 2.2–4.2% (Allain et al., 1992;
Tortevoye et al., 2005) and it is around of 3.8–4.3% in rural Haitian
populations (Schill et al., 1989; Grant et al., 1992). Furthermore,
some series of ATL and TSP/HAM have been reported mainly in
immigrants from this island living in France and the US (Vernant
et al., 1987; Bhagavati et al., 1988; Gout et al., 1989; Gessain et al.,
1990a; Besson et al., 2001). In the French West Indies (FWI: Mar-
tinique and Guadeloupe), HTLV-1 seroprevalence in blood donors
is around 0.3–0.4% (Cesaire et al., 1999; Rouet et al., 1999a,b) and
in pregnant women from Martinique it is of around 2% (Denis
et al., 1988; Mansuy et al., 1999). Furthermore, few hundreds of
TSP/HAM and of ATL have been reported during the last 25 years
in these islands (Vernant et al., 1987; Plumelle et al., 1993) and
in immigrants in Metropolitan France (Gout et al., 1989; Gessain
et al., 1990a,c; Besson et al., 2001). HTLV-1 is also endemic at a
similar level in Trinidad and Tobago (Blattner et al., 1990; Daisley
et al., 1991) as well as in Barbados (Riedel et al., 1989).
In contrast, the studies performed in Cuba indicated that
HTLV-1 seroprevalence is very low in this island (Hernandez
Ramirez et al., 1991; Silva Cabrera et al., 1997) with also only very
few ATL or TSP/HAM cases reported (Estrada et al., 1995). This is
very probably linked, partly, to the different ethnic background of
the islands with relatively few persons of African ancestry in Cuba
as compared to Jamaica, Haiti, or the French West Indies. The esti-
mates of the number of HTLV-1 infected persons for some islands
in the Caribbean are given in Table 2.
HTLV-1 IN ASIA
Asia is the world’s largest and most populous continent with
nearly 3.9 billion people (60% of the world’s current human pop-
ulation). Here we arbitrarily defined four subregions: (1) East
Asia (China, Japan, North and South Korea, Mongolia, and Tai-
wan), (2) North (Siberia), Central (Afghanistan, Iran, Kazakhstan,
Kyrgyzstan, Turkmenistan, and Uzbekistan,) and Southwest Asia
(Arabian Peninsula, Armenia, Georgia, Israel, Jordan, Lebanon,
Syria, and Turkey), (3) South Asia (Bangladesh, Bhutan, India,
Nepal, Pakistan, and Sri Lanka,) and (4) Southeast Asia (Brunei,
Burma, Cambodia, Indonesia, Laos, Malaysia, Philippines, Sin-
gapore, Thailand, East Timor, and Vietnam). Except for some
very important endemic foci including mainly Japan and Iran, the
prevalence of HTLV-1 and associated diseases in Asia seems very
low. However, in most of the areas, due to the lack of large and
representative studies, the situation remains still poorly known.
East Asia
East Asia comprises more than 1.4 billion people (about 20% of
the world population). In Mainland China, no general population-
based-study has been performed to our knowledge regarding
HTLV-1 prevalence. However, a large-scale study concerning
145,293 blood donors representative of 13 provinces revealed a
very low global prevalence (0.013%; Wang et al., 2005). Interest-
ingly, all HTLV-1 seropositive individuals originate from the Fujian
province in the Southeast and the prevalence rate in this pecu-
liar province reached 0.055%. This confirmed the prevalence rate
(0.06%) previously found in the same province among healthy
individuals (Wang et al., 2004). Concerning the HTLV-1 related
diseases, while very few cases of TSP/HAM have been reported
(Seyfert et al., 2004), some series of ATL cases were found in Chi-
nese patients (Zhuo et al., 1995; Au and Lo, 2005). These ATL cases
were mainly distributed in patients from the coastal provinces and
the Southeast China especially in the Fujian province.
In Japan, HTLV-1 infection has been extensively studied for
more than 30 years. Japan is one of the most important foci
of HTLV-1 infection and associated diseases (Watanabe, 2011).
Indeed, around 1,000 of ATL cases are diagnosed each year (Tajima,
1990) and several hundreds of TSP/HAM have been reported
(Osame et al., 1990), as well as large series of other HTLV-1 associ-
ated diseases including uveitis (Mochizuki et al., 1992). The mini-
mal global prevalence of HTLV-1 infection in Japan as determined
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by screening of blood donors is estimated to be at least 1.08 million
in 2006 (Satake et al., 2012). Based on a previous nationwide sur-
vey, performed also among blood donors, the number of HTLV-1
infected individuals was around 1.2 million (Tajima, 1990). For
several reasons, the prevalence calculated from blood donors sur-
vey is very probably lower than the actual value (Satake et al.,
2012). Thus, Japan comprises very probably the largest HTLV-1
carriers number in the world. Since the first studies, the reparti-
tion of HTLV-1 carriers in Japan is quite uneven with prevalence
rates among blood donors varying from 1% in Hokkaido to more
than 6% in Kyushu and Okinawa Islands in the Southern part of
the archipelago (Hinuma et al., 1982; Maeda et al., 1984; Tajima,
1990). Several studies in pregnant women also revealed such a
heterogeneous situation, which origin remains to be determined,
with an HTLV-1 prevalence ranging from 0.5% (in North/central
Japan) to 5.8% (Southern part of the country; Oki et al., 1992;
Umemoto et al., 1994; Goto et al., 1997; Maehama, 2004). In some
villages or towns of highly endemic areas, HTLV-1 prevalence can
reach 30–40% in adults, aged more than 50 years old (Kohakura
et al., 1986; Tajima et al., 1987). Several programs aimed to prevent
HTLV-1 transmission from mother to child, by refraining HTLV-1
infected mothers to breast-fed their children, have been imple-
mented with great success (Hino, 2011). Although the HTLV-1
prevalence in Japan is very high, it is not clear why neighboring
regions such as East China or Korea have a low prevalence. Indeed,
the studies among Korean blood donors from various districts of
Korea revealed very low HTLV-1 seropositive rates (0.007–0.25%;
Lee et al., 1986; Kim et al., 1999; Kwon et al., 2008). Furthermore,
very few cases of ATL and TSP/HAM have been reported in Korean
patients (Park et al., 1991; Saito et al., 1993; Jeon et al., 2000).
In Taiwan, slightly more data are available and the prevalence
of HTLV-1 infection seems higher. HTLV-1 screening in six blood
centers revealed indeed an HTLV-1 seropositivity rate of 0.058%
(Lu et al., 2001). Furthermore, in the Taiwanese adult population,
aged more than 30 years, the HTLV-1 prevalence varies from 0.82
to 1.63% according to the districts investigated (Chen et al., 1999).
Lastly, series of ATL cases have been diagnosed in Taipei (Lee et al.,
2010).
North, Central, and Southwest Asia
Sporadic HTLV-1 infection cases have been detected in various
small ethnic populations of Northern and Eastern Siberia, espe-
cially among individuals from the Nivikhi group (Seniuta et al.,
1990; Gessain and de The, 1996). These data suggest the possible
existence of HTLV-1 foci, which makes impossible a global esti-
mation of the HTLV-1 prevalence in these vast regions. In Central
Asia, Iran is by far the most studied country, especially the area of
Mashad in the Northeast of the country. According to the type of
studies and of tested populations, HTLV-1 prevalence is estimated
to range from 0.77 to 3% in adults (Safai et al., 1996; Abbaszadegan
et al., 2003; Rafatpanah et al., 2011). A more recent study indicates
an HTLV-1 prevalence of 1.66% in adults from the city of Sabzevar
located in the Southeast of Mashad and confirmed that HTLV-1
is highly endemic in this region (Azarpazhooh et al., 2012). Fur-
thermore, relatively large series of ATL as well as TSP/HAM cases
originating from the Mashad region are reported in Iran (Sidi
et al., 1990; Kchour et al., 2009) but also in Iranian immigrants
living in European countries, the United States, or Israël (Sidi et al.,
1990; Gabarre et al., 1993; Miller et al., 1998). No data are avail-
able from other areas of central Asia except scarce findings from
Turkmenistan where the HTLV-1 seroprevalence rate among blood
donors reached 0.2% (3/1,510; Senyuta et al., 1998).
In Southwest Asia, the HTLV-1 infection appeared to be non-
endemic. In Saudi Arabia, there is no case of HTLV-1 infection
or extremely low HTLV-1 seroprevalence rates (0.002–0.0052%)
reported among blood donors (Bernvil et al., 1997; Arif and
Ramia, 1998; El-Hazmi, 2004). The situation is quite comparable
in other Persian Gulf countries such as Kuwait where the HTLV-
1 seroprevalence observed among blood donors reached 0.009%
(Al-Mufti et al., 1997). Nevertheless, few symptomatic HTLV-1
cases have been described in this latter country (Voevodin et al.,
1995) and Iraq (Denic et al., 1990).
In Israel, an immigration state, studies indicated that most of
infected persons originated from highly endemic countries (Iran,
Romania, and Africa). Thus, the HTLV-1 prevalence must be
appreciated according to the donors’ countries of origin. However,
the HTLV-1 prevalence in blood donors born in Israel reached
0.001% (Stienlauf et al., 2009). Furthermore, some ATL and
TSP/HAM cases have been described mainly among immigrants
of Romanian or Iranian origin (Sidi et al., 1990; Shtalrid et al.,
2005).
In Lebanon, none of 1,900 blood donors screened was seropos-
itive for HTLV-1 (Naman et al., 2002) although one ATL case
of Lebanese origin has been described (Bitar et al., 2009). Quite
comparable situation is observed in Turkey where none among
10,000 Healthy blood donors was HTLV-1 seroreactive (Sertoz
et al., 2010). No data are available, to our knowledge, concerning
the HTLV-1 situation in Jordan, Syria, and Armenia.
South Asia
India is with China, the second most populated country in the
world with 1.2 billion inhabitants. If we consider neighboring
countries such as Pakistan, Bangladesh, Sri lanka, and Nepal
plus Bhutan and Maldives territories, the South Asian population
reached 1.6 billion (a quarter of the world population). In this
region, the studies concerning HTLV-1 prevalence are scarce and
the most recent one among Indian blood donors revealed a 0.14%
prevalence rate (Kumar and Gupta, 2006). Other study demon-
strated no serological evidence of HTLV-1 infection among the
pregnant women tested (Ramalingam et al., 2001). Despite the low
HTLV-1 prevalence rate, some ATL, and TSP/HAM cases have been
regularly reported especially in Southern India (Andhra Pradesh,
Kerala, and Tamil Nadu; Chandy et al., 1991; Babu et al., 1993; Jain
et al., 2008; Ahmed et al., 2012) and Western India (Singhal et al.,
1993). Thus, the prevalence of HTLV-1 carriers in India seems
rare but taken into account the huge population size, large-scale
studies are necessary to assess the global prevalence rate before to
conclude that this infection is a minor public health hazard and to
estimate a reliable HTLV-1 prevalence rate.
In Bangladesh, despite the large population size, no HTLV-1
prevalence study has been performed. A sporadic occurrence of
HTLV-1 infection (0.9%) was found among patients with motor
neuron disease called neurolathyrism (Haque et al., 1994). In Pak-
istan, who shares with Bangladesh the same population size, no
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data concerning HTLV-1 prevalence is available. This situation is
quite the same in others South Asian territories such as Nepal, Sri
Lanka, Bhutan, and Maldives archipelago where HTLV-1 infection
has never been investigated to our knowledge.
Southeast Asia
The Southeast Asian region comprises more than half a billion
individuals. However, the situation regarding the HTLV-1 preva-
lence in the most populated countries has been poorly described.
In Indonesia, the few studies revealed no HTLV-1 carrier among
the blood donors tested (Tanggo et al., 2000). In Philippines, anec-
dotal, and ancient study suggested that the infection is present
in the general population (Ishida et al., 1988). In the neighbor-
ing countries such as Malaysia, Vietnam, Cambodia, Laos, and
Burma, no reliable information is available concerning the HTLV-
1 global epidemiology. Moreover, no evidence of HTLV-1 infection
among Hmong individuals from Northern Thailand was reported
(Louisiriotchanakul et al., 2000) and a study performed on Hmong
refugees living in French Guyana confirmed this data (Tortevoye
et al., 2000). The situation seems quite different in the eastern
part of New Guinea Island called Irian Jaya, where sporadic cases
of HTLV-1 infection have been reported in some small isolated
tribes (Re et al., 1989). Despite the lack of population-based stud-
ies in the Southeast Asian populations, the HTLV-1 prevalence rate
seems to be low.
HTLV-1 IN OCEANIA
Oceania is a vast zone between continental Asia and the Americas
comprising mostly coral atolls and volcanic islands. It is divided
into three subregions, Micronesia (Kiribati, Marshall Islands, and
Nauru), Australo-Melanesia (Australia, Fiji Islands, New Cale-
donia, Papua New Guinea, Solomon Islands, and Vanuatu), and
Polynesia (American Samoa, Cook Islands, Easter Island, French
Polynesia, Hawaii, New Zealand, Samoa, Tonga, Tuvalu,Wallis, and
Futuna). The population is around 35 millions individuals with
two third of Australian origin.
Australo-Melanesia
Only few population-based-study using solid serological confir-
mation criteria have been performed regarding HTLV-1 preva-
lence in the Australo-Melanesian region. Interestingly, few studies,
conducted among Papuan aboriginal populations, demonstrated
that some remote tribes as the Hagahai population living in the
highlands (Madang province), exhibited higher HTLV-1 preva-
lence rate than population groups originating from different
Papuan provinces such as the Sepik province (Yanagihara et al.,
1990; Sanders et al., 1993; Yamaguchi et al., 1993; Takao et al.,
2000). In the Solomon Islands, the HTLV-1 seroprevalence rate
range from 1.2 to 3% according to the populations (hospitalized
individuals, blood donors) and the islands investigated (Yanagi-
hara et al., 1991; Nicholson et al., 1992; Furusyo et al., 1999). In
Vanuatu archipelago, a large-scale population-based-study (4,247
individuals mostly adults) showed that the HTLV-1 prevalence
rate was of 0.62% (Cassar et al., 2007). In Fiji and New Caledonia
archipelagoes, no HTLV-1 infection was brought out by the very
few studies performed among the native-born populations tested
(Louis et al., 1990; Nicholson et al., 1992; Chungue et al., 1993).
In Australia, the situation for HTLV-1 is quite different as
we considered Aboriginal populations from Central Australia or
blood donors comprising mainly white non-Aboriginal individ-
uals living in coastal areas. Thus, the studies conducted among
blood donors from main Australian cities (Adelaide, Brisbane,
Melbourne, Perth, and Sydney) revealed that HTLV-1 preva-
lence rate is very low, comprised between 0.001 and 0.032%
(Whyte, 1997; Polizzotto et al., 2008). In contrast, several stud-
ies indicated that the Aboriginal groups of inland Australian
regions represent a high HTLV-1 endemic population (May et al.,
1988; Einsiedel et al., 2010, 2012). Moreover, HTLV-1 related
cases, ATL and/or TSP/HAM, have been described among the
Aboriginal communities of central Australia (Kirkland et al.,
1991; Rajabalendaran et al., 1993), Papua New Guinea (Yanagi-
hara et al., 1990), and the Solomon Islands (Ajdukiewicz et al.,
1989).
Polynesia/Micronesia
The few reliable studies performed in Polynesia/Micronesia
regarding the HTLV-1 prevalence among native-born Polyne-
sian individuals, indicated that the infection is absent or very
rare (Nicholson et al., 1992; Chungue et al., 1993; Ohkura
et al., 1999). In the Hawaiian archipelago, the virus is present
but the studies suggested that HTLV-1 was introduced with
the Japanese immigration (Kimata et al., 1989). Indeed, ATL
and TSP/HAM cases were observed among immigrants from
Southern Japan and their descendants (Yim et al., 1986; Yanag-
ihara et al., 1989; Dixon et al., 1990). Few other studies have
described the HTLV-1 situation in the Cook Islands, Kiribati,
New Zealand, the Samoa and Wallis, and Futuna, but no HTLV-
1 seropositive case has been documented to date (Reddy et al.,
1987; Louis et al., 1990; Nicholson et al., 1992; Chungue et al.,
1993).
CONCLUSION
Our best estimates range approximately from 5 to 10 millions
HTLV-1 infected individuals. However, these results were only
based on nearly 1.5 billion of individuals originating from known
HTLV-1 endemic areas with reliable available epidemiological
data. Correct estimates in other highly populated regions, such
as China, India, the Maghreb, and East Africa, is currently not pos-
sible. The real number of HTLV-1 carriers is thus very probably
much higher.
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